Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2019-03-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
平安证券股份有限公司关于普莱柯生物工程股份有限公司首次公开发行募投项目结项并将节余募集资金永久补充流动资金的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from Ping An Securities regarding the completion of the initial public offering (IPO) fundraising projects of Pulike Bioengineering Co., Ltd. and the permanent supplementation of surplus raised funds into working capital. It references regulatory requirements, fundraising amounts, project changes, and the use of surplus funds. The document is a formal verification and opinion letter from the sponsor institution, not the actual fundraising report or financial statements. It is relatively short (4134 characters) and serves as a regulatory compliance and verification filing rather than a full financial report or announcement of voting results. Therefore, it fits best under Regulatory Filings (RNS) as it does not contain full financial statements or detailed financial analysis but is a compliance and verification document related to fundraising use.
2019-03-29 Chinese
2018年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the 2018 annual report summary of Pulike Bioengineering Co., Ltd. It contains detailed financial data for the year 2018, including total assets, revenue, net profit, quarterly financial data, and other financial indicators. It also includes company business overview, management discussion and analysis, accounting policy changes, and information about subsidiaries. The document is over 7,000 characters and contains substantive financial data and analysis, not just an announcement or certification. The presence of audited financial data and comprehensive business and financial information aligns with the characteristics of an Annual Report (10-K equivalent). Therefore, the document should be classified as an Annual Report (10-K). FY 2018
2019-03-29 Chinese
2018年年度报告
Annual Report Classification · 100% confidence The document is titled "2018 年年度报告" which translates to "2018 Annual Report". It contains detailed sections typical of an annual report such as company overview, financial data, management discussion and analysis, risk disclosures, and audited financial statements. The document length is substantial (15,000 characters) and includes comprehensive financial and operational information for the fiscal year 2018. It also mentions an audit report with an unqualified opinion, which is commonly included in annual reports. There is no indication that this is merely an announcement or a summary; rather, it is the full annual report itself. FY 2018
2019-03-29 Chinese
控股股东及其他关联方占用资金情况的专项审计说明
Regulatory Filings
2019-03-29 Chinese
内部控制审计报告
Regulatory Filings
2019-03-29 Chinese
第三届董事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of 普莱柯生物工程股份有限公司 on March 29, 2019. It lists multiple agenda items approved by the board, including approval of the 2018 annual report, board work report, general manager's report, independent directors' report, audit committee report, internal control reports, financial statements, profit distribution plan, and other governance matters. The document repeatedly states that the detailed content of these reports is available on the Shanghai Stock Exchange website and that these matters still require shareholder approval. The document is not the actual annual report or financial statements but a board meeting resolution announcement summarizing decisions made and referring to external sources for full reports. It also includes approval of management appointments and remuneration. Given the nature of the document as a board meeting resolutions announcement, it fits best under the category of Board/Management Information (MANG). The document length is 2499 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full report. Therefore, the classification is MANG with high confidence.
2019-03-29 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.